



COPY OF PAPERS
ORIGINALLY FILED

PATENT

674
2/16/02

I hereby certify that on the date specified below, this correspondence is being deposited with the United States Postal Service as first-class mail in an envelope addressed to the Commissioner for Patents, Washington, DC 20231.

Date

June 21, 2002

John T. Oliver

John T. Oliver

RECEIVED

JUL 02 2002

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

TECH CENTER 1600/2901

Applicant : Emad S. Alnemri
Application No. : 10/067,615
Filed : February 4, 2002
For : TRAIL RECEPTORS, NUCLEIC ACIDS ENCODING
THE SAME, AND METHODS OF USE THEREOF

Art Unit : 1646
Docket No. : 480140.432D1
Date : June 21, 2002

Commissioner for Patents
Washington, DC 20231

INFORMATION DISCLOSURE STATEMENT


Commissioner for Patents:

In accordance with 37 C.F.R. §§ 1.56 and 1.97 through 1.98, applicant wishes to make known to the Patent and Trademark Office the 17 references set forth on the attached Forms PTO-1449. This application is a Divisional and relies, under 35 U.S.C. § 120, on the earlier filing date of prior USAN 09/134,618, filed August 14, 1998. The references listed on the attached Forms PTO-1449 were submitted to and/or cited by the Patent and Trademark Office in this prior application and, therefore, are not required to be provided in this application. If the Examiner wishes, copies will be provided upon request. However, reference AA (US 6,261,801) on page 1 of the attached Forms PTO-1449 was not submitted to and/or cited by the Office in this prior application and is being submitted herewith.

As to any reference supplied or made of record on the attached Forms PTO-1449, applicant does not admit that it is "prior art" under 35 U.S.C. §§ 102 or 103, and specifically reserves the right to traverse or antedate any such reference, as by a showing under 37 C.F.R. § 1.131 or other method. Although the aforesaid references are made known to the Patent and Trademark Office in compliance with applicant's duty to disclose all information he is aware of which is believed relevant to the examination of the above-identified application, applicant believes that his invention is patentable.

Please acknowledge receipt of this Information Disclosure Statement and kindly make the cited references of record in the above-identified application.

Respectfully submitted,
Emad S. Alnemri
Seed Intellectual Property Law Group PLLC



William T. Christiansen, Ph.D.
Registration No. 44,614

WTC:jto

Enclosures:

Postcard
Forms PTO-1449 (2 Sheets)
Cited Reference

701 Fifth Avenue, Suite 6300
Seattle, Washington 98104-7092
Phone: (206) 622-4900
Fax: (206) 682-6031

JOHNO295538_1.DOC

TECH CENTER 1600/2900
JUL 02 2002

RECEIVED

FORM PTO-1449
(REV. 7-80)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
480140.432D1APPLICATION NO.
10/067,615

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

APPLICANT

Emad S. Alnemri

FILING DATE

February 4, 2002

GROUP ART UNIT

1646

U.S. PATENT DOCUMENTS

*EXAMINER INITIALS	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
AA	0,261,801	07/17/01	Wei et al.	435	69.1	
AB						
AC						
AD						
AE						
AF						
AG						
AH						
AI						
AJ						

COPY OF PAPERS
ORIGINALLY FILED

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
					YES	NO
	AK	WO 98/30693	07/16/98	PCT		
	AL	WO 98/35986	08/20/98	PCT		
	AM	EP 867 509 A2	09/30/98	EPO		
	AN	EP 870 827 A2	10/14/98	EPO		

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

AO	Chaudhary et al., "Death Receptor 5, a New Member of the TNFR Family, and DR4 Induce FADD-Dependent Apoptosis and Activate the NF- κ B Pathway," <i>Immunity</i> 7: 821-830, 1997.
AP	Degli-Esposti et al., "Cloning and Characterization of TRAIL-R3, a Novel Member of the Emerging TRAIL Receptor Family," <i>J. Exp. Med.</i> 186(7): 1165-1170, 1997.
AQ	MacFarlane et al., "Identification and Molecular Cloning of Two Novel Receptors for the Cytotoxic Ligand TRAIL," <i>The Journal Of Biological Chemistry</i> 272(41): 25417-25420, 1997.

EXAMINER

DATE CONSIDERED

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

ATTY. DOCKET NO.

480140.432D1

APPLICATION NO.

10/067,615

APPLICANT

Emad S. Alnemri

FILING DATE

February 4, 2002

GROUP ART UNIT

1646

JUN 27 2002

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
----------------------	-----------------	------	------	-------	----------	-------------------------------

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION
					YES NO
	BA				
	BB				
	BC				
	BD				

COPY OF PAPERS
ORIGINALLY FILED

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

	BE	Mikayama et al., "Molecular cloning and functional expression of a cDNA encoding glycosylation-inhibiting factor," <i>Proc. Natl. Acad. Sci. USA</i> 90:10056-10060, November 1993.
	BF	Pan et al., "An Antagonist Decoy Receptor and a Death Domain-Containing Receptor for TRAIL," <i>Science</i> 277: 815-818, 1997.
	BG	Schneider et al., "Characterization of two receptors for TRAIL," <i>FEBS Letters</i> 416: 329-334, 1997.
	BH	Screaton et al., "TRICK2, a new alternatively spliced receptor that transduces the cytotoxic signal from TRAIL," <i>Current Biology</i> 7: 693-696, 1997.
	BI	Sheridan et al., "Control of TRAIL-Induced Apoptosis by a Family of Signaling and Decoy Receptors," <i>Science</i> 277: 818-821, 1997.
	BJ	Suter and Pauli, "Cloning of the cDNA encoding the porcine p55 tumor necrosis factor receptor," <i>Gene</i> 163: 263-266, 1995.
	BK	Voet et al., <i>Biochemistry</i> , John Wiley & Sons, Inc., 1990, pages 126-128 and 228-234.
	BL	Walczak et al., "TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL," <i>The EMBO Journal</i> 16(17): 5386-5397, 1997.
	BM	Wu et al., "KILLER/DR5 is a DNA damage-inducible p53-regulated death receptor gene," <i>Nature Genetics</i> 17: 141-143, 1997.
	BN	

EXAMINER

DATE CONSIDERED

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).